Therefore, currently existing and future cancer therapies based on the inhibition of individual components of the Sema-Plexin-NRP-VEGF complex have to take in account different cancer histotypes where distinct semaphorins and their either individual or cross-binding receptors are differently expressed and regulated. Here, VEGFA is linked to cancer.